In this video, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the benefit of early detection and interception in patients with multiple myeloma. Dr Ghobrial explains the importance of screening for precursor conditions, and further emphasizes the benefit of treating at the smoldering myeloma stage. Following this, Dr Ghobrial highlights the benefit of precision interception and the added value of using immunotherapy at an earlier stage. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.